WallStreetZenWallStreetZen

NASDAQ: REGN
Regeneron Pharmaceuticals Inc Earnings & Revenue

Open Broker Account

REGN past earnings growth

How has REGN's earnings growth performed historically?
Company
-24.09%
Industry
15.98%
Market
40.77%
REGN's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
REGN's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
REGN's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

REGN past revenue growth

How has REGN's revenue growth performed historically?
Company
1.24%
Industry
117.46%
Market
174.68%
REGN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
REGN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
REGN's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

REGN earnings and revenue history

Current Revenue
$13.7B
Current Earnings
$5.4B
Current Profit Margin
39.2%
REGN's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

REGN Return on Equity

Current Company
26.6%
Current Industry
-9.7%
Current Market
-8.3%
REGN's Return on Equity (26.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when REGN announces earnings.

REGN Return on Assets

Current Company
20.1%
Current Industry
0.7%
REGN is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

REGN Return on Capital Employed

Current Company
24.57%
Current Industry
11.4%
REGN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

REGN vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
REGN$13.71B$6.41B$5.37B+19.97%+33.04%
VRTX$8.70B$4.23B$3.27B+30.53%+74.11%
MRNA$21.39B$13.68B$11.77B+225.07%+67.35%
BNTX$18.20B$14.35B$10.12B+487.71%+17.07%
GMAB$1.59B$1.07B$747.88M+123.86%+128.11%

REGN earnings dates

Next earnings date
Feb 2, 2023

Regeneron Pharmaceuticals Earnings & Revenue FAQ

What were REGN's earnings last quarter?

On Invalid Date, Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q3 2022 earnings per share (EPS) of $12.31, up 19.91% year over year. Total Regeneron Pharmaceuticals earnings for the quarter were $1.32 billion. In the same quarter last year, Regeneron Pharmaceuticals's earnings per share (EPS) was $15.37.

If you're new to stock investing, here's how to buy Regeneron Pharmaceuticals stock.

What was REGN's earnings growth in the past year?

As of Q4 2022, Regeneron Pharmaceuticals's earnings has grown -24.09% year over year. This is 40.07 percentage points lower than the US Biotechnology industry earnings growth rate of 15.98%. Regeneron Pharmaceuticals's earnings in the past year totalled $5.37 billion.

What is REGN's earnings date?

Regeneron Pharmaceuticals's earnings date is Invalid Date. Add REGN to your watchlist to be reminded of REGN's next earnings announcement.

What was REGN's revenue last quarter?

On Invalid Date, Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q3 2022 revenue of $2.94 billion up 14.96% year over year. In the same quarter last year, Regeneron Pharmaceuticals's revenue was $3.45 billion.

What was REGN's revenue growth in the past year?

As of Q4 2022, Regeneron Pharmaceuticals's revenue has grown 1.24% year over year. This is 116.22 percentage points lower than the US Biotechnology industry revenue growth rate of 117.46%. Regeneron Pharmaceuticals's revenue in the past year totalled $13.71 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.